Company intelligence / Profile preview

Sotira

Phoenix, Arizona, United Statessotira.org.cy ↗

Ownership: Private
Development stage: Other

Overview

Sotira developed KEPTIDE™, an intranasal peptide designed to block the ACE2 receptor, preventing SARS-CoV‑2 entry into human cells. Preclinical studies showed protection against lung and kidney injury and prevention of acute death response in animal models. As of late 2020, the product was under FDA review with plans to enter Phase 1 human trials in spring 2021. No published results from human clinical trials are available.

Therapeutic areas: Infectious Diseases
Modalities: PeptidesSmall molecule
Industry: Biotech

Drug pipeline

1 asset

KEPTIDE

Preclinical

Partnerships

Coppe Laboratories

Beyond the preview

Go deeper on Sotira.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sotira.

Explore the full profile